ACIU AC Immune SA

8.7
-0.03  -0%
Previous Close 8.73
Open 8.75
Price To Book 1.98
Market Cap 586,257,491
Shares 67,362,690
Volume 5,882
Short Ratio
Av. Daily Volume 94,284
Stock charts supplied by TradingView

NewsSee all news

  1. AC Immune to Present at Jefferies 2019 London Healthcare Conference

    LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced

  2. AC Immune Q3 2019 Financial Results and Business Update

     CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC

  3. AC Immune Hosts Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

    Company Provides Key Updates on Tau Pipeline Candidates LAUSANNE, Switzerland, Nov. 06, 2019 (GLOBE NEWSWIRE) --  AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad

  4. AC Immune to Host Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

    LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced

  5. AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program

    Lilly to pay CHF30 million development milestone Recognizes progress in ACI-3024 Small Molecule Tau Morphomer™ development LAUSANNE, Switzerland, Sept. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 data due 3Q 2020.
RG6100 (Anti-Tau RO7105705)
Alzheimer’s disease
Phase 1/2 interim data released July 2019.
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 2 trial initiation announced August 20, 2018.
ACI-24
Alzheimer’s disease
Phase 2 trial initiation announced February 20, 2019.
MTAU9937A
Alzheimer’s disease
Phase 2 trial planned for 1H 2019.
ACI-35
Alzheimer’s disease
Phase 1 trial initiation announced July 17, 2019.
ACI-3024
Alzheimer’s disease
Phase 1b/2 trial initiation announced August 1, 2019.
ACI-35.030
Alzheimer’s Disease

Latest News

  1. AC Immune to Present at Jefferies 2019 London Healthcare Conference

    LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced

  2. AC Immune Q3 2019 Financial Results and Business Update

     CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC

  3. AC Immune Hosts Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

    Company Provides Key Updates on Tau Pipeline Candidates LAUSANNE, Switzerland, Nov. 06, 2019 (GLOBE NEWSWIRE) --  AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad

  4. AC Immune to Host Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

    LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced

  5. AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program

    Lilly to pay CHF30 million development milestone Recognizes progress in ACI-3024 Small Molecule Tau Morphomer™ development LAUSANNE, Switzerland, Sept. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a

  6. AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620

    Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer's and neurodegenerative diseases The clinical milestone highlights the strength of AC Immune's Tau pipeline, one of the

  7. AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson's Disease Diagnostic Imaging Agent

    LAUSANNE, Switzerland, Sept. 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced